Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare

Siew Eng Choon,1 Mark G Lebwohl,2 Slaheddine Marrakchi,3 A David Burden,4 Tsen-Fang Tsai,5 Akimichi Morita,6 Alexander A Navarini,7 Min Zheng,8 Jinhua Xu,9 Hamida Turki,3 Sushmita Rajeswari,10 Hongjie Deng,11 Kay Tetzlaff,12 Christian Thoma,13 Hervé Bachelez14,15

ABSTRACT

Introduction Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening disease characterised by recurrent flares of widespread neutrophilic aseptic skin pustular eruption. Despite the availability of approved biologics for GPP in Japan, Taiwan and Thailand, associated evidence is largely based on uncontrolled studies in which acute flares were not directly assessed. Therefore, there is a high unmet need to investigate new rapid-acting effective treatments that resolve symptoms associated with acute GPP flares. A prior Phase I proof-of-concept study showed rapid improvements in skin and pustule clearance with a single intravenous dose of spesolimab, a novel anti-interleukin-36 receptor antibody, in patients presenting with an acute GPP flare. Here, we present the design and rationale of Effisayil 1, a global, Phase II, placebo-controlled study to evaluate the efficacy, safety and tolerability of spesolimab in patients presenting with an acute GPP flare.

Methods and analysis At least 51 patients with an acute GPP flare will be randomised 2:1 to receive a single 900 mg intravenous dose of spesolimab or placebo and followed for up to 28 weeks. The primary endpoint is a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 0 (pustule clearance) at Week 1. The key secondary endpoint is a GPPGA score of 0 or 1 (clear or almost clear) at Week 1. Safety will be assessed over the study duration by the occurrence of treatment-emergent adverse events. Blood and skin biopsies will be collected to assess biomarkers. Superiority of spesolimab over placebo in the proportion of patients achieving the primary and key secondary endpoints will be evaluated.

Ethics and dissemination The study complies with the ethical principles of the Declaration of Helsinki, the International Council for Harmonisation’s Good Clinical Practice and local regulations. Ethics committee approvals have been obtained for each centre from all participating countries and are listed in online supplementary file 1.

Strengths and limitations of this study

- To our knowledge, this is the first randomised, double-blind, placebo-controlled study in patients presenting with an acute generalized pustular psoriasis (GPP) flare.
- This study will be the largest randomised, placebo-controlled trial conducted in this population to date.
- This study will incorporate clinically relevant disease-specific measures to assess the efficacy of spesolimab, an anti-interleukin-36 receptor antibody for which rapid improvements in skin and pustule clearance has been observed in a previous Phase I single-arm study in seven patients presenting with acute GPP.
- This study will provide robust evidence on the efficacy of spesolimab in patients with acute GPP flares and will allow the natural course of disease to be characterised.
- A major challenge for the study is the recruitment of patients achieving the primary endpoint.

Primary results will be published in a peer-reviewed journal.

Trial registration details ClinicalTrials.gov identifier: NCT03782792; Pre-results.

INTRODUCTION

Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening autoinflammatory neutrophilic skin disease characterised by episodes of widespread eruption of aseptic, macroscopically visible pustules,
which can occur with or without plaque psoriasis, and may be accompanied by systemic inflammation. GPP is usually associated with one or several systemic symptoms such as fever, malaise and fatigue, and extraneous manifestations such as arthritis, uveitis, acute respiratory distress syndrome, cardiovascular shock and neutrophilic cholangitis. Common laboratory abnormalities include elevated C-reactive protein, leucocytosis, neutrophilia and liver function abnormalities. Acute GPP flares are associated with significant morbidity, and without appropriate treatment, mortality. GPP is highly heterogeneous, with some patients experiencing frequent flares, that is, several episodes per year, while for others, flares may occur less frequently, potentially years apart. Acute GPP flares may be triggered by infections, stress, medication, medication withdrawal (eg, corticosteroids) and pregnancy, causing a dramatic reduction in quality of life. During the disease course, some patients with GPP may experience relapsing disease with recurrent flares, or persistent disease with intermittent flares. The clinical appearance of the disease can be phenotypically heterogeneous; skin may be clear in between episodic acute flares or patients may have persistent disease characterised by ill-defined erythematous plaques with or without pustules, which may be localised or widespread.

Therapeutic intervention in GPP is a major challenge globally. The rarity of GPP means recruitment of sufficient patients to conduct large, randomised, controlled trials to robustly investigate the efficacy and safety of therapeutics is a constant challenge. In addition, the intermittent remission and spontaneously self-limiting episodic pustular flares characteristic of GPP make it difficult to assess the efficacy of any intervention in this population. Therefore, there is still a lack of robust evidence to guide treatment decisions for GPP. Available management guidelines for GPP are widely based on anti-plaque psoriasis strategies, limited case studies and single-arm, open-label studies and generally recommend ciclosporin, retinoids, infliximab and methotrexate as first-line therapies. Use of conventional systemic therapy may be associated with cumulative toxicities and limited efficacy, making them inappropriate for long-term disease control. Although there are therapies specifically indicated for GPP approved in Japan, Taiwan and Thailand, there are currently no approved GPP-specific therapies for acute GPP flares globally. In Japan, tumour necrosis factor (TNF)-alpha inhibitors (adalimumab, infliximab and certolizumab pegol), interleukin-(IL)-17/IL-17 receptor (IL-17R) inhibitors (secukinumab, brodalumab and ixekizumab) and IL-23 inhibitors (risankizumab and guselkumab) are approved for the treatment of patients with GPP who have had an inadequate response to conventional therapy. The approval of TNF inhibitors was based largely on case studies, whereas the approval of IL-17/IL-17R and IL-23 inhibitors was based on prospective, but small-scale, open-label, single-arm, Phase III studies, in which non-disease-specific endpoints, such as any improvement in the Clinical Global Impression index, were used to assess efficacy in Japanese patients presenting with mild-to-moderate GPP as per the Japanese Dermatological Association severity score. As systemic and skin manifestations of acute GPP flares may remit within 2 months in some patients, in most of these trials, clinical assessment of endpoints were conducted at Week 16, and did not measure clinically meaningful aspects such as the rapid improvement or resolution of painful pustules. In Taiwan and Thailand, brodalumab was approved for the treatment of adults with pustular psoriasis who are candidates for systemic therapy, or adults with GPP who have had an inadequate response to conventional therapy, respectively, both based on a Japanese open-label study which included only 12 patients with GPP.

Effective treatments with a very rapid onset of action for acute GPP flares that can allow early control of skin inflammation and the prevention of complications, including pustule formation and systemic manifestations, and are tolerable for both short- and long-term treatment strategies are needed. In patients with GPP, overexpression of IL-36 inflammatory cytokines in skin lesions and loss-of-function mutations in the gene coding for the IL-36 receptor antagonist (IL36RN), as well as mutations in other genes connected with the IL-36 pathway (eg, CARD14, APJIS3, SERPINA3), have been identified in genetic studies for some patients, suggesting that the IL-36 pathway may be central to GPP pathogenesis. Reports for the presence of IL36RN mutations in patients with GPP have ranged between 10% and 82%, and was lower in cases of GPP associated with plaque psoriasis than in those associated with GPP alone. Moreover, the knockout of the IL-36R in a murine model of deficiency of IL-36R antagonist (DITRA) led to complete resolution of skin inflammation, making the blockade of IL-36R signalling a novel and appealing targeted therapeutic approach for patients with GPP.

Results of a Phase I, proof-of-concept study, in which the safety and efficacy of a single intravenous dose of spesolimab (BI 655130), an anti-IL-36R humanised monoclonal antibody, was assessed in seven patients with an acute GPP flare, provided the first evidence for targeting the IL-36 pathway. In this study, spesolimab resulted in rapid (within 7 days) and sustained improvements (up to last assessment at Week 20) in clinical signs and symptoms irrespective of IL36RN mutation, suggesting that IL-36 plays a pathogenic role among patients with GPP with different genetic backgrounds; this was accompanied by rapid downregulation of molecular signatures from the innate immune response, including neutrophilic pathways, and Th1/Th17-mediated inflammation. Four patients (57.1%) had mild-to-moderate drug-related adverse events through Week 20, but no severe or serious adverse events were reported. This study showed that spesolimab is a promising targeted therapy for acute GPP.
patients presenting with an acute GPP flare (ClinicalTrials.gov identifier: NCT03782792). GPP-specific clinical measures that assess key manifestations of the disease, the Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) and GPPGA pustulation subscore, have been established to evaluate treatment efficacy in this study. The GPPGA is a physician-based assessment of the severity of pustules, erythema and scaling of GPP lesions; each component is scored on a 5-point scale, ranging from 0 (clear) to 4 (severe), and the average is calculated (see online supplementary file 2). To differentiate against placebo with a feasible sample size, a stringent primary endpoint was chosen—achievement of a GPPGA pustulation subscore of 0 (complete pustular clearance) at Week 1. The successful early performance of these scores was demonstrated in the Phase 1 proof-of-concept study. A GPPGA score of 0 or 1 (clear or almost clear skin) was achieved in five of seven patients by Week 1 and in all patients by Week 4.40 The acuteness, severity and potentially life-threatening consequences of other autoinflammatory diseases and the effectiveness shown for the blockade of the IL-1 family, such as the achievement of early inactive disease and sustained remission,42 43 further support the rationale for using an early efficacy endpoint in patients with GPP. The evaluation of non-pustulation components (erythema and scaling) are to be evaluated as part of the key secondary endpoint, the achievement of a total GPPGA score of 0 or 1.

Here, we describe the rationale, study design and methods of Effisayil 1; to our knowledge, this is the first randomised, double-blind, placebo-controlled study in this patient population presenting with an acute GPP flare. This novel and innovative study will inform on the efficacy and safety of targeting the IL-36 pathway in patients with GPP, and will provide insights into the natural progression of untreated GPP disease through the placebo arm, as well as historical clinical data with particular focus on previous occurrence of flares.

METHODS AND ANALYSIS

Study objectives

The primary objective of the Effisayil 1 study is to evaluate the efficacy, safety and tolerability of spesolimab versus placebo in patients presenting with an acute GPP flare. Further objectives include the assessment of pharmacokinetics, anti-drug antibodies and pharmacogenomics of spesolimab, and the exploration of biomarkers in acute GPP. In addition, the natural course of GPP in patients receiving placebo, the response of systemic symptoms of GPP flares to spesolimab and the effects of delaying treatment and further dosing with spesolimab in patients with insufficient initial response will also be explored.

Eligibility criteria

Patients aged 18 to 75 years with GPP, defined by the European Rare And Severe Psoriasis Expert Network (ERASpEN) at screening,1 who satisfy the inclusion criteria are allowed to enrol into the study regardless of whether they are experiencing a flare at the time of screening, as patients in remission can be monitored for up to 6 months for their next acute flare. If required, screening and randomisation can occur on the same visit if patients meet the randomisation criteria (laboratory testing to be conducted by a local laboratory in such instances).

Patients will be enrolled if they have previous evidence of fever associated with flares before randomisation, and/or mild asthenia, and/or myalgia, and/or elevated C-reactive protein, and/or leucocytosis with peripheral blood neutrophilia above the upper limit of normal, and meet one of the following criteria, regardless of IL36RN mutation status:

- Have a GPPGA score of 0 or 1 and a known and documented history of GPP, or
- Are experiencing an acute GPP flare of moderate-to-severe intensity, or
- Are experiencing their first episode of an acute GPP flare of moderate-to-severe intensity; the diagnosis of GPP is to be confirmed retrospectively by a central external expert committee.

Patients eligible for this trial must comply with all of the following inclusion and exclusion criteria at randomisation.

Inclusion criteria

Patients must be experiencing an acute GPP flare of moderate-to-severe intensity prior to randomisation, defined in the trial as:

- A GPPGA score of ≥3
- New appearance or worsening of existing pustules
- A GPPGA pustulation subscore of ≥2
- ≥5% body surface covered with erythema and the presence of pustules.

Exclusion criteria

Patients will be excluded if they are presenting with:

- Synovitis-acne-pustulosis-hyperostosis-osteitis syndrome.
- Erythrodermic plaque psoriasis without pustules or with pustules restricted to psoriatic plaques.
- Drug-triggered acute generalized exanthematous pustulosis.
- Immediate life-threatening flare of GPP or requiring intensive care treatment.
- Dose escalation of their maintenance treatment with ciclosporin, retinoids or methotrexate within 2 weeks prior to randomisation.
- Treatment with any drug, including biologics and systemic drugs considered likely to interfere with the safe conduct of the study or any prior exposure to an IL-36R inhibitor.

Full inclusion and exclusion criteria and restricted concomitant medication can be found in the online supplemental file 2 and online supplemental table 1.

Randomisation and intervention

At least 51 patients presenting with an acute GPP flare are to be randomised to receive a single 900 mg intravenous dose of spesolimab or placebo in a 2:1 ratio on Day 1. Study drug is allocated using computerised Interactive Response Technology and patients and investigators involved will remain blinded until after database lock, unless emergency unblinding is required. This allocation ratio will enable more patients with a distressing and potentially life-threatening disease to be on treatment. This design is also likely to be more appealing to patients because evidence has shown that patients prefer to participate in clinical trials where there is a greater likelihood of receiving active treatment. As required by some regulatory agencies, and based on the rapid onset of response demonstrated in the Phase 1, proof-of-concept study and the lack of licensed active interventions, the use of a placebo-controlled parallel group was considered most appropriate to evaluate the efficacy and safety of spesolimab in patients with an acute GPP flare.

Escape and rescue medication

If the severity and progression of the disease worsens within the first week after randomisation and requires immediate treatment, the investigator can treat the patient with escape medication, which is the investigator’s choice of standard of care (SoC). However, if the disease condition is stable, it is recommended to wait until the primary endpoint visit (Day 8/Week 1) before prescribing a SoC escape medication because there will be an option to administer open-label spesolimab instead at this time. Due to the absence of an approved standard treatment for GPP and a commonly accepted treatment algorithm, patients in this trial are likely to have a heterogeneous pre-treatment history, given that different SoC are available in different countries.

After Week 1, only one rescue dose with open-label spesolimab is permitted if a patient who previously achieved a clinical response (GPPGA 0 or 1) experiences recurrence of a GPP flare. Patients who do not achieve a clinical response, but have disease worsening subsequent to Week 1, can receive an escape treatment chosen by the investigator.

Study locations and timings

The study will enrol patients from across 52 centres in 12 countries; it started in March 2019 and it is expected to complete in 2021. After randomisation, patients will be assessed daily until Day 3. Clinical visits on Days 4 to 7 are optional and need not be attended if a patient has already achieved complete pustular clearance (GPPGA pustulation subscore of 0). After patients have received a single dose of spesolimab or placebo at Day 1, patients will be followed for 12 to 28 weeks based on the subsequent treatment response (figure 1). Patients who have not received escape treatment, and who have a GPPGA subscore of 2 and a pustular component of GPPGA subscore of 2 at Week 1, will qualify for treatment with an open-label single intravenous dose of 900 mg spesolimab on Day 8. All randomised patients will continue through the subsequent visits until the end of study. Patients who show no flare symptoms of moderate-to-severe intensity at the end of the study and meet clinical criteria for treatment response at Week 12, or at the subsequent visit for patients on rescue treatment with open-label spesolimab (figure 1), will be eligible to enter a 5-year open-label extension study (ClinicalTrials.gov identifier: NCT03886246). Those not qualifying to enter the open-label extension study, will be followed for up to an additional 16 weeks. Clinical response, photographs of skin lesions, physical examination, examination of vital signs, fever assessment and safety laboratory tests are to be undertaken at each visit. Optional skin biopsies will be taken on Days 1 and 8 and Week 8. Whole blood for RNA sequencing and serum for soluble protein biomarkers are to be sampled prior to dosing, on Days 1 to 3 and Day 8, Week 2, 4 and 12 and at the end of study visit. Importantly, the IL36RN mutation status is to be determined for all patients.

Study endpoints

The primary endpoint of the study is a GPPGA pustulation subscore of 0 at Week 1 and the key secondary endpoint is a GPPGA score of 0 or 1 at Week 1. Secondary endpoints at Week 4 included in the statistical strategy are a 75% improvement in the Psoriasis Area and Severity Index for Generalized Pustular Psoriasis (GPPASI 75), change from baseline in pain Visual Analogue Scale (VAS) score, change from baseline in Psoriasis Symptom Scale (PSS) score and change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score.

The GPP-specific clinical efficacy endpoints (GPPGA, GPPASI) were created with minimal modification of the PGA and PASI (replacement of the induration component with pustulation), which are widely used and understood clinical instruments by dermatologists, and were created with the help of leading global experts in GPP and psoriasis vulgaris. The proposed primary endpoint of a GPPGA pustulation subscore of 0 (clear) at Week 1 and the key secondary endpoint of a GPPGA score of 0 or 1 at Week 1 are clinically meaningful as pustules are the primary lesion of the disease and reflect the desired rapid pustule clearance and overall improvement in GPP skin symptoms. Other secondary endpoints include the occurrence of treatment-emergent adverse events. At each visit, GPPGA and GPPASI will be measured to assess sustained efficacy (table 1).

At each applicable visit, patients will be asked to complete patient-reported outcomes (PROs) questionnaires. The order of completion for PROs is recommended to be as follows: PSS, Dermatology Life Quality Index (DLQI), pain VAS, FACIT-Fatigue and 5-level EuroQoL-5 dimensions (EQ-5D-5L). Correlations between efficacy endpoints and PROs are to be assessed. The full
list of study outcomes is reported in table 1 and online supplemental table 2.

The assessment of biomarkers will be exploratory. This will include biochemical and cellular biomarkers in skin and blood samples pre-treatment and post-treatment with spesolimab. Changes in gene and protein expression in optional skin biopsies, in patients who give consent, are to be assessed. Gene expression analysis will include the genes involved in the mechanism of action of spesolimab or the pathology of the disease. Immunohistochemistry for neutrophils, macrophages, keratinocytes, T cells and dendritic cells markers are planned. Serum will be collected to assess changes in soluble protein levels of select IL-36 pathway disease-specific biomarkers. Cellular biomarkers on cells such as T cells and macrophages will be assessed by flow cytometry from whole blood samples. In addition, RNA sequencing from one blood sample of IL36RN, CARD14 and APIS3 genes to assess known GPP-associated mutations will be performed in whole blood, and their potential influence on the severity of disease and efficacy of spesolimab will be evaluated.

**Statistical analysis**

The trial is designed to demonstrate the superiority of spesolimab with regard to the primary endpoint (achievement of pustule clearance at Week 1) and the key secondary endpoint (achievement of GPPGA 0 or 1 at Week 1) relative to placebo. With an expected response rate of 0.6 on spesolimab and 0.1 on placebo for the primary endpoint and key secondary endpoint, and a type I error of <0.025 (one-sided), for a
Primary outcome
- GPPGA pustulation subscore of 0
- Week 1

Key secondary outcome
- GPPGA score of 0 or 1
- Week 1

Secondary endpoints
- GPPASI 75
- Week 4
- Change from baseline in VAS score
- Week 4
- Change from baseline in PSS score
- Week 4
- Change from baseline in FACIT-Fatigue score
- Week 4
- GPPGA score of 0 or 1
- Week 4
- GPPGA pustulation subscore of 0
- Week 4

Percentage reduction from baseline in GPPASI
- Weeks 1 and 4

Further endpoints
- Time to first achievement of a GPPGA score of 0 or 1
- --
- Time to first achievement of a GPPGA pustulation subscore of 0
- --
- Improvement of CGI per JDA severity index
- Weeks 1, 2 and 4
- GPPGA total score of 0 or 1
- By visit
- GPPGA pustulation subscore of 0
- By visit
- Change from baseline in GPPGA total score
- By visit
- Change from baseline in GPPGA pustulation subscore
- By visit
- GPPASI 50
- By visit
- GPPASI 75
- By visit
- Overall percent reduction in GPPASI
- By visit
- Change from baseline in DLQI score
- By visit
- Change from baseline in FACIT-Fatigue score
- By visit
- Change in pain VAS score
- By visit
- Change in PSS score
- By visit
- DLQI score of 0 or 1
- By visit
- Change from baseline in EQ-5D-5L VAS score
- By visit

Endpoints that will also be explored on patients receiving OL spesolimab at Day 8.

*Endpoints that will also be explored on patients receiving OL spesolimab at Day 8.

Ethics and dissemination
The study will be conducted in compliance with the protocol, the ethical principles of the Declaration of Helsinki, in accordance with the International Council for Harmonisation’s Guideline for Good Clinical Practice (GCP), and the EU regulation 536/2014, the Japanese GCP regulations (Ministry of Health and Welfare Ordinance No. 28, 27 March 1997) and applicable local regulations, and is approved by the ethics committees of participating institutions and countries. A list of all ethical approvals is provided in online supplementary file 1. Approved amendments of the protocol will be posted on ClinicalTrials.gov (last protocol V.3, 26 June 2020). Eligible patients will be provided information and informed consent will be obtained (see online supplementary file 3).

On completion of the trial and after finalisation of the clinical trial report, the study results will be published in an international peer-reviewed medical journal and abstracts for congresses.

Data management
Patient privacy will be ensured by using patient identification code numbers. Data protection and data security measures are implemented for the collection, storage and processing of patient data in accordance with the confidentiality and privacy principle 12 of the WHO GCP handbook.

Patient and public involvement
There was no involvement from patients and the public in the design of this study.

DISCUSSION
Randomised controlled trials are the gold standard for testing the efficacy and safety of new treatments. However, in rare severe diseases, recruitment difficulties and ethical concerns often hamper the possibility of involving a large population in a placebo-controlled randomised trial. Furthermore, although randomised controlled studies have been conducted in rare autoinflammatory syndromes such as cryopyrinopathies with canakinumab,13 GPP raised an additional major challenge due to the spontaneously self-limiting course of acute flares in its intermittent pattern that can occur
in some patients. Therefore, an original study design integrating these parameters was necessary to accurately assess the efficacy of any drug intervention in this rare variant of the psoriatic disease spectrum. Effisayil 1 is the first randomised, double-blind, placebo-controlled study conducted in patients presenting with an acute GPP flare. Altogether, the high number of participating countries to minimise the risk of under-recruiting, along with the rapidity of the efficacy assessment and the lack of a suitable comparator, propitiates the ambitious design and conduct of this unique trial in a rare disease. This study aims to address a high unmet medical need and the lack of robust efficacy and safety data in patients with acute GPP flares, assess PROs, systemic symptoms and biomarkers and their correlation with clinical response and severity of disease, and provide insights on the natural disease course of an acute GPP flare. Results from this trial are planned to support the first registration of spesolimab in patients with GPP.

The study will evaluate the efficacy and safety of a single intravenous injection of spesolimab at Week 1 versus placebo, with an option of an open-label dose at Day 8 for both treatment arms if criteria are met. In addition, the study will allow the duration of efficacy to be assessed for up to 28 weeks, if not rolling over into the open-label extension study. All recurrent flares within 12 weeks after a single or two intravenous doses of spesolimab will be recorded. Pictures of skin lesions as well as lesion absence will be systematically collected at each visit to provide further visual insights. For each case, naturally occurring resolution or worsening of symptoms in the placebo arm will provide insights on the natural disease course of GPP flare.

Despite the small population size of the study and the single 900 mg dose, Effisayil 1 is designed to be the largest study in patients with GPP, and the first randomised, placebo-controlled trial in this population to date. In addition to this study there are two further studies planned including a 5-year open-label extension study and the Effisayil 2 study (ClinicalTrials.gov identifier: NCT04999837), a multicentre, randomised, parallel-group, double-blind, placebo-controlled, Phase IIb, dose-finding study to evaluate the efficacy and safety of subcutaneous spesolimab compared with placebo in the prevention of GPP flares in patients with a history of GPP. These studies will tackle different disease scenarios that address the limitations of the present study.

Overall, the results of the Effisayil 1 trial will provide robust evidence on early intervention with spesolimab for the treatment of acute GPP flares and will establish the relevance of using disease-specific endpoints that are clinically meaningful for patients and their physicians.

Contributors All authors meet the ICMJE criteria for authorship. SEC, MGL, SM, ADB, SR, HD, CT and HB were involved in the conception and trial design. HD provided statistical expertise. SEC, MGL, SM, ADB, TFF, AM, AAN, MZ, JX, HT, SR, HD, KT, CT and HB contributed in drafting the protocol manuscript and critically revised and commented on its previous versions and the final version. SEC, MGL, SM, ADB, TFF, AM, AAN, MZ, JX, HT, SR, HD, KT and HB will be involved in the analysis and/or interpretation of the data.

Funding This study is funded by Boehringer Ingelheim. Editorial assistance in BMJ Open and the preparation of this manuscript was provided by Ester Ruiz-Romeu, PhD, Leigh Church, PhD and Tina Borg, PhD, of OPEN Health Communications (London, UK) and funded by Boehringer Ingelheim. The authors would like to acknowledge the contributions made by David Hall, Hauri Hua and Arno Schlosser in the design and conduct of this study. Agreements between Boehringer Ingelheim and the authors included the confidentiality of the study data. All authors collaborated on the writing of the manuscript, and made the decision to submit the manuscript for publication.

Competing interests SR is an employee of Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA. HD is an employee of Boehringer Ingelheim Investment Co Ltd, Shanghai, China. KT is an employee of Boehringer Ingelheim GmbH, Ingelheim, Germany. CT is an employee of Boehringer Ingelheim International GmbH, Biberach, Germany. SEC declares paid activities as advisor, speaker or consultant for AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, Leo Pharma, MSD, Novartis, Pfizer, Sanofi and UCB. MGL declares paid consulting activities for Aditum Bio, Allergan, Almirall, Arcutis, Inc, Avotres Therapeutics, BirchBioMed Inc, BMD skinco, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inzyme Pharma, Kyowak Kirin, Leo Pharma, Meji Seika Pharma, Menlo, Mitsubishi, NeuroDerm, Pfizer, Promius (Dr Reyder’s Laboratories Ltd), Serono, Theravance and Verrica, and research funds from AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Incyte, Janssen Research & Development, LLC, LEO Pharma, Ortho Dermatologics, Pfizer and UCB. SM and HT declare paid consulting activities for Boehringer Ingelheim. ADB declares paid consulting activities for AbbVie, Almirall, Boehringer Ingelheim, Celgene, Janssen, LEO Pharma, Lilly, Novartis and UCB. TFF declares conducting clinical trials or paid consulting activities for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, Janssen-Cilag, LEO Pharma, Merck Sharp & Dohme, Novartis International, Pfizer and UCB Pharma. AM declares receiving research grants, consulting fees and/or speaker’s fees from AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Eisai, Janssen, Kyowa Hakko Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe, Nichi-Iko, Nippon Kayaku, Novartis, Sun Pharmaceutical Industries, Taiho Pharmaceutical and Torii Pharmaceutical and Ushio. AAN declares being a consultant and advisor and/or receiving speaking fees and/or grants and/or served as an investigator in clinical trials for AbbVie, Almirall, Amgen, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, GSK, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Sandø, Sanofi, Serono and UCB. MZ declares receiving grants, consulting fees, and/or speaker’s fees from AbbVie, Boehringer Ingelheim, Janssen-Cilag, LEO Pharma China, Novartis, Pfizer Inc and Xian-Janssen. JX declares receiving grants, consulting fees, and/or speaker’s fees from AbbVie, Boehringer Ingelheim, Novartis, Pfizer Inc and Sanofi. HB declares paid consulting activities for AbbVie, Almirall, BIOCAD, Boehringer Ingelheim, Celgene, Janssen, Kyowa-Kirin, LEO Pharma, Lilly, Mylan, Novartis and UCB, and grant support from Boehringer Ingelheim, Janssen, LEO Pharma, Novartis and Pfizer.

Patient consent for publication Not required.

Author affiliations
2 Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan
3 Department of Dermatology, University Hospital Basel, Basel, Switzerland
4 Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China
5 Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China
6 Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA
7 Boehringer Ingelheim (China), Investment Co Ltd, Shanghai, China
8 Boehringer Ingelheim International GmbH, Ingelheim, Germany
9 Boehringer Ingelheim International GmbH, Biberach, Germany
10 Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, Paris, France
11 INSERM U1163, Imagine Institute for Genetics of Human Diseases, Université de Paris, Paris, France
REFERENCES


31 Lumicef® (brodalumab), TDS5 assessment report; 2018.

32 Lumicef® (brodalumab), Thaliland FDA product information; 2018.


